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CASE PRESENTATION
A 56-year-old Hispanic woman with a history of sarcoidosis
came to the Emergency Department complaining of
bilateral leg pain. One year before admission, she had
presented to another hospital with shoulder pain and
weight loss. At that time, she was found to have
hypercalcemia and acute renal failure. Computed
tomography of the chest revealed mediastinal and hilar
lymphadenopathy, and a transbronchial needle biopsy was
consistent with sarcoidosis. She was treated with
intravenous fluids, a bisphosphonate, and steroids, which
were tapered off over 2 months. Her creatinine level
decreased from 4.5 to 1.3 mg per 100 ml. One month before
admission, she had been checked by a primary care doctor
for a routine visit, and lab tests included a creatinine level
of 5.1 mg per 100 ml. Past medical history was also notable
for hypertension and a hysterectomy. Her medications
included amlodipine and intermittent naproxen (she
reported only having taken four pills recently of naproxen).
Physical examination revealed a well-appearing
woman. The blood pressure was 132/82 and there was
mild diffuse tenderness on palpation of her legs
bilaterally. There was no rash. Her lungs were clear.
The heart was regular in rate and rhythm with no
murmurs, rubs, or gallops. No lymphadenopathy or
hepatosplenomegaly was appreciated. There was no
lower extremity edema. Laboratory values and radiology
results are shown in Table 1. She was initially treated with
intravenous fluids and furosemide. Her calcium level was
normalized, but her creatinine level continued to rise.
A renal biopsy was performed.
RENAL BIOPSY FINDINGS
Of the 10 glomeruli sampled, 3 were globally sclerotic. Four
glomeruli located in zones of interstitial fibrosis displayed
global mild retraction of the tuft with wrinkling of
glomerular basement membranes and Bowman’s capsular
sclerosis. The remaining glomeruli were unremarkable. The
cortical interstitium was diffusely expanded by moderate-
to-severe fibrosis, edema, and inflammation. The interstitial
leukocytes consisted of lymphocytes, monocytes, and numer-
ous multinucleated giant cells forming multifocal granulomas
(Figure 1). The granulomas ranged from small to large and
from discrete to confluent, without evidence of central
necrosis or caseation (Figure 2). Most giant cells were of the
Langhans type, some containing birefringent asteroid bodies
and calcified basophilic Schaumann bodies (Figure 3). There
was focal tubulitis with tubular degenerative and regenerative
changes. Tubular atrophy affected 60% of the cortex. There
was moderate arteriosclerosis and arteriolosclerosis.
Special stains (acid fast bacilli and Gomori methenamine
silver) were negative for acid fast bacilli and fungal
organisms. Routine immunofluorescence was negative for
immunoglobulins and complement in all compartments,
with the exception of granular staining for C3 involving some
tubular basement membranes. By electron microscopy, the
glomeruli were unremarkable. The interstitium displayed
granulomatous inflammation including giant cells that
contained electron-dense concretions consistent with Schau-
mann bodies. There was focal lymphocytic tubulitis and
acute tubular injury. No tubulo-interstitial electron-dense
deposits were identified.
PATHOLOGIC DIAGNOSIS
Granulomatous interstitial nephritis (GIN), severe, active,
and chronic, was consistent with renal sarcoidosis. Arterio-
sclerosis was moderate.
CLINICAL FOLLOW-UP
The patient was started on prednisone 100 mg day1,
amlodipine 2.5 mg day1, and subcutaneous epoetin alpha
14 000 U three times weekly. At 2 weeks, the prednisone was
tapered to 100 mg every other day, and mycophenolate
mofetil (MMF) 500 mg twice daily was added. Figure 4 shows
the time course of the patient’s serum creatinine and serum
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calcium over the first 15 days following presentation. At 1
month, her creatinine level had decreased to 2.2 mg per
100 ml. Amlodipine was changed to ramipril, and epoetin-a
Table 1 | Diagnostic tests on admission
Value (reference range)
Serum/blood
Urea nitrogen 44 mg per 100 ml (7–20 mg per 100 ml)
Creatinine 8.9 mg per 100 ml (0.5–0.9 mg per 100 ml)
Calcium 14.1 mg per 100 ml (8.4–9.8 mg per 100 ml)
Phosphorus 6.7 mg per 100 ml (2.5–4.3 mg per 100 ml)
White blood cells 9.4 109 l1 (3.54–9.06 109 l1)
Hemoglobin 9.9 g per 100 ml (12.0–15.8 g per 100 ml)
Hematocrit 28.3% (35.4–44.4%)
Platelets 455 109 l1 (165–415 109 l1)
Total protein 8.0 g per 100 ml (6.7–8.6 g per 100 ml)
Albumin 3.6 g per 100 ml (4.0–5.0 g per 100 ml)
Urine
Urinalysis Negative for blood and protein
Microscopy 3 WBC hpf1, 0–3 RBC hpf1, 1+ triple
phosphate crystals (0–3 WBC hpf1,
0–3 RBC hpf1)
24-h protein 1071 mg (50–150 mg)
Urine protein
electrophoresis
Negative
Serologic tests
Angiotensin-converting
enzyme
231 U l1 (0–90 U l1)
Serum protein
electrophoresis
Negative
Hepatitis B surface
antigen
Negative
Hepatitis C antibody Negative
Radiology
Chest radiograph Fine reticular pattern at the bilateral lung
bases, left greater than right
Renal ultrasound Normal echogenicity; right kidney 9.0 cm;
left kidney 9.2 cm, with small
nonobstructing calculus
hpf, high-powered field.
Figure 1 | A low power view shows the widespread effacement
of tubulo-interstitial architecture by confluent granulomatous
inflammation and interstitial fibrosis, causing broad
separation and focal loss of tubular basement membranes
(Jones methenamine silver, original magnification  100).
Figure 2 | This field shows several small discrete granulomas
containing multinucleated giant cells surrounded by
lymphocytic infiltrates, without evidence of caseation or
central necrosis. The adjacent glomerulus displays thickening
of its Bowman’s capsule, but it is otherwise unremarkable
(Jones methenamine silver, original magnification  400).
Figure 3 | Many of the interstitial giant cells contain
intracytoplasmic inclusions, some of which are basophilic,
consistent with Schaumann bodies. Under polarized light
(not illustrated), some of the stellate inclusions were birefringent,
consistent with asteroid bodies (hematoxylin and eosin,
original magnification  400).
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Figure 4 | The patient’s serum creatinine (closed circles, solid
line) and serum calcium (open circles, dashed line) are plotted
against time for the first 15 days following presentation.
Renal biopsy was performed on day 2.
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was discontinued. At 2 months, the prednisone was
decreased to 80 mg every other day, and then slowly tapered
to off over the next 3 months. MMF was changed to
mycophenolate sodium because the patient complained of
abdominal pain and diarrhea. The mycophenolate sodium
was titrated up to 720 mg twice daily, and she remained
asymptomatic on this dose. At her most recent follow-up, 18
months after the biopsy, the creatinine level was 1.8 mg
per 100 ml.
DISCUSSION
Sarcoidosis is a multisystem disorder of unknown etiology,
characterized by granuloma formation. Most commonly, it
affects the lungs, skin, and eyes, but it can impact all organs,
including the kidney. Although clinically apparent renal
involvement is considered rare, one series found renal
abnormalities of various types in 48% of patients with
chronic sarcoidosis (but none with acute sarcoidosis).1
A summary of the renal manifestations of sarcoidosis is
presented in Table 2.
The most common renal manifestation is related to
abnormal calcium metabolism. In patients with sarcoidosis,
the incidence of hypercalcemia is 10–20% and that of
hypercalciuria is 40–50%.2 The cause of hypercalcemia is
1-hydroxylation of 25(OH) vitamin D to form 1,25(OH)2
vitamin D in the macrophages of sarcoid granulomas.3 This
leads to increased intestinal absorption of calcium, increased
bone resorption, and calciuria (with or without hypercalce-
mia). Hypercalciuria can lead to acute renal failure by causing
concentrating defects, nephrocalcinosis, or nephrolithiasis;
renal function may be further impaired by hypercalcemia-
induced vasoconstriction, decreasing glomerular filtration
rate, and causing tubular ischemia. Irreversible renal damage
from nephrocalcinosis is rare, occurring in less than 2% of
patients.2 In addition to the tubular effects of calcium
metabolism, renal tubular acidosis and inappropriate gluco-
suria can be present.4
Nephrolithiasis occurs in up to 15% of patients with
sarcoidosis, and in approximately 4% of patients, it may be
the presenting feature of the disease.5,6 Obstructive uropathy
may result from nephrolithiasis, but in patients with
sarcoidosis, obstruction may also be due to retroperitoneal
fibrosis or lymphadenopathy leading to ureteral obstruction.7
Primary glomerular disease in patients with sarcoidosis
is rare. However, there are case reports associating sarcoidosis
with minimal-change disease, focal segmental glomerulo-
sclerosis, membranous nephropathy, IgA nephropathy,
membranoproliferative glomerulonephritis, proliferative
and crescentic glomerulonephritis, and Anti-neutrophil
cytoplasmic antibodies (ANCA)-positive crescentic glomer-
ulonephritis.8 The mechanism for glomerular involvement
of sarcoidosis is unclear, and a causal relationship has not
been proven.
A more common manifestation of sarcoidosis in the
kidney is granulomatous infiltration of the renal parenchyma.
Although autopsy studies reveal granulomas in the kidneys of
20% of patients with sarcoidosis,9 clinically significant disease
related to granuloma formation is less common and difficult
to prove due to the frequent coexistence of nephrocalcinosis.
In a series of 46 patients with sarcoidosis, 15 had renal
abnormalities. Of the 10 biopsied, 6 had nephrocalcinosis,
2 had GIN, 1 had non-GIN, and 1 had GIN and IgA-
nephropathy.1 Table 3 summarizes some of the larger adult
case series of GIN from sarcoidosis.
The pathologic findings of GIN consist of interstitial
collections of epitheliod histiocytes, giant cells, and lympho-
cytes forming granulomas. In sarcoidosis, the granulomas are
small, well defined, and noncaseating. The presence of
Schaumann bodies (laminated intracytoplasmic concretions)
within the granulomas is pathognomonic for sarcoidosis.
Immunofluorescence or electron microscopic studies are
unrevealing.18
The differential diagnosis for GIN is broad. The most
common etiology is allergic (drug-induced) (25–45%),
followed by sarcoidosis (9–29%). Other causes include
Wegeners granulomatosis (8–16%), infections (9–25%),
foreign-body giant cell reaction, and tubulointerstitial
nephritis and uveitis syndrome. Drugs that are particularly
related to GIN include b-lactam antibiotics and anti-
convulsants. Tuberculosis is the most common infection
related to GIN, although fungal pyelonephritis, for instance
related to histoplasmosis, has been reported, particularly in
immunocompromised patients.19,20 There have also been
associations reported between sarcoidosis and tubulointer-
stitial nephritis and uveitis syndrome, a condition usually
affecting young women, manifested by renal and bone
marrow granulomas and uveitis.21
Rarely, renal sarcoidosis may lead to end-stage renal
disease, most commonly with severe nephrocalcinosis.
A review of five patients with renal sarcoidosis leading
Table 2 | Renal manifestations of sarcoidosis
Calcium dysregulation
Hypercalciuria
Hypercalcemia
Renal tubular acidosis
Nephrolithiasis
Obstructive uropathy
Retroperitoneal lymphadenopathy
Retroperitoneal fibrosis
Tubulointerstitial disease
Nephrocalcinosis
Granulomatous interstitial nephritis
Non-granulomatous interstitial nephritis
Glomerular disease (rare, association unclear)
Minimal change disease
Focal segmental glomerulosclerosis
Membranous nephropathy
IgA nephropathy
Membranoproliferative glomerulonephritis
Proliferative and crescentic glomerulonephritis
ANCA-positive crescentic glomerulonephritis
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to end-stage renal disease and kidney transplantation found
that two of the patients developed recurrent disease in
the graft, in both cases successfully managed with cortico-
steroids.22
The standard treatment for sarcoidosis has been cortico-
steroids, usually started at the equivalent of prednisone
1 mg kg1 day1. As shown in Table 3, there is usually an
impressive response, but relapses are frequent, particularly
when steroids are tapered. These relapses usually respond to
reinitiation of steroids, but most patients are left with chronic
renal dysfunction from interstitial fibrosis. In a recent series
of 17 patients with sarcoid granulomatous nephritis, all were
treated initially with prednisolone 0.5 mg kg1 day1 and
then tapered to maintenance doses of 5–7.5 mg day1. Three
of 17 (18%) relapsed upon ceasing therapy and responded to
reinitiation of corticosteroids, 1 (6%) ceased therapy and was
lost to follow-up and represented an end-stage renal failure,
and 2 (12%) had multiple relapses and were successfully
managed with the addition of mycophenolate mofetil and
azathioprine, respectively.23
Patients who are steroid-intolerant or steroid-resistant have
been treated with cyclophosphamide, infliximab, azathioprine,
and MMF with varying degrees of success.16,23–26 In a case
series of six patients, the addition of azathioprine to a steroid
regimen enabled the taper of prednisone to 5–7.5 mg day1 in
four of five patients.16
Mycophenolate mofetil has been used to treat nonrenal
sarcoidosis. One patient with uveitis from sarcoidosis
improved when MMF was added to his preexisting regimen
of steroids and cyclosporine.27 Five patients with mucocu-
taneous sarcoidosis (although without renal manifestations)
who either were steroid-intolerant or had steroid-resistant
disease were successfully treated with MMF.28 There is a
report of a patient with ANCA-negative crescentic glomer-
ulonephritis associated with duodenal and pancreatic sarcoi-
dosis with recurrent duodenitis and pancreatitis with each
attempt at steroid taper. MMF was started and enabled a
prednisone taper to 4 mg day1. The patient remained in
remission at 15 months, at which time MMF
was discontinued.29 MMF has been added to steroid
regimens in two case series of renal sarcoidosis (four patients
in total) to enable steroid tapering to low doses.16,30 There
has been only one case report of renal-limited sarcoidosis
being successfully treated with MMF monotherapy. This
patient, a 15-year-old boy, presented with a creatinine level of
7.2 mg per 100 ml. He was treated with pulsed solumedrol for
3 days, followed by prednisone 40 mg twice daily for 2
months, then 60 mg daily for 1 month, at which time his
creatinine level had decreased to 1.4 mg per 100 ml. At this
point, MMF was added as a steroid-sparing agent, and
titrated up to 1000 mg twice daily. Steroids were tapered to
off over the following 4 months, and his creatinine level
remained at 1.1 mg per 100 ml. At 1 year, the MMF was
decreased to 500 mg twice daily and benazepril was added.
His creatinine level was 1.1 mg per 100 ml at 21 months after
disease onset.25T
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CONCLUSION
In summary, renal failure from sarcoid-related GIN is
uncommon. When it occurs, it is almost always sensitive to
steroids, but tends to relapse when steroids are tapered. There
are few data on steroid-sparing regimens in patients with
relapsing sarcoidosis, and MMF and azathioprine may be
considered in this situation.
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